{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:10:56Z","timestamp":1789081856814,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848016001"],"award-info":[{"award-number":["848016001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00198-020-05378-0","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T08:02:25Z","timestamp":1588320145000},"page":"1645-1669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review"],"prefix":"10.1007","volume":"31","author":[{"name":"On behalf of the European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cornelissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"de Kunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"5378_CR1","doi-asserted-by":"publisher","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","DOI":"10.1007\/s11657-013-0136-1"},{"key":"5378_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-015-0089-z","volume":"98","author":"FJB L\u00f6tters","year":"2016","unstructured":"L\u00f6tters FJB, van den Bergh JP, de Vries F et al (2016) Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int 98:235\u2013243. https:\/\/doi.org\/10.1007\/s00223-015-0089-z","journal-title":"Calcif Tissue Int"},{"key":"5378_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23\u201357. https:\/\/doi.org\/10.1007\/s00198-012-2074-y","journal-title":"Osteoporos Int"},{"key":"5378_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00198-015-3084-3","volume":"26","author":"C Klop","year":"2015","unstructured":"Klop C, Welsing PMJ, Elders PJM, Overbeek JA, Souverein PC, Burden AM, van Onzenoort H, Leufkens HG, Bijlsma JW, de Vries F (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int 26:1831\u20131840. https:\/\/doi.org\/10.1007\/s00198-015-3084-3","journal-title":"Osteoporos Int"},{"key":"5378_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","volume":"22","author":"JC Netelenbos","year":"2011","unstructured":"Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in the Netherlands. Osteoporos Int 22:1537\u20131546. https:\/\/doi.org\/10.1007\/s00198-010-1372-5","journal-title":"Osteoporos Int"},{"key":"5378_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049","journal-title":"BMJ Open"},{"key":"5378_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00223-009-9329-4","volume":"86","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Rabenda V, Gathon HJ et al (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202\u2013210. https:\/\/doi.org\/10.1007\/s00223-009-9329-4","journal-title":"Calcif Tissue Int"},{"key":"5378_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jval.2010.11.010","volume":"14","author":"S Ross","year":"2011","unstructured":"Ross S, Samuels E, Gairy K et al (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Heal 14:571\u2013581. https:\/\/doi.org\/10.1016\/j.jval.2010.11.010","journal-title":"Value Heal"},{"key":"5378_CR9","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"CT Yeam","year":"2018","unstructured":"Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29:2623\u20132637. https:\/\/doi.org\/10.1007\/s00198-018-4759-3","journal-title":"Osteoporos Int"},{"key":"5378_CR10","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00198-013-2364-z","volume":"24","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Salas M, Hughes DA et al (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907\u20132918. https:\/\/doi.org\/10.1007\/s00198-013-2364-z","journal-title":"Osteoporos Int"},{"key":"5378_CR11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1001\/jama.2018.19271","volume":"320","author":"V Kini","year":"2018","unstructured":"Kini V, Ho PM (2018) Interventions to improve medication adherence: a review. JAMA 320:2461\u20132473. https:\/\/doi.org\/10.1001\/jama.2018.19271","journal-title":"JAMA"},{"key":"5378_CR12","doi-asserted-by":"publisher","unstructured":"Hiligsmann M, Cornelissen D, Vrijens B et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal. Osteoporos Int:1\u201311. https:\/\/doi.org\/10.1007\/s00198-019-05104-5","DOI":"10.1007\/s00198-019-05104-5"},{"key":"5378_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.b2700","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:1\u201334. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"J Clin Epidemiol"},{"key":"5378_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:1\u20136. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"5378_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1440-172X.2008.01722.x","volume":"15","author":"E Lehane","year":"2009","unstructured":"Lehane E, McCarthy G (2009) Medication non-adherence\u2014exploring the conceptual mire. Int J Nurs Pract 15:25\u201331. https:\/\/doi.org\/10.1111\/j.1440-172X.2008.01722.x","journal-title":"Int J Nurs Pract"},{"key":"5378_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691\u2013705. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04167.x","journal-title":"Br J Clin Pharmacol"},{"key":"5378_CR17","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ Published Online First. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"5378_CR18","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ Published Online First. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"5378_CR19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M et al (2014) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12:1495\u20131499. https:\/\/doi.org\/10.1016\/j.ijsu.2014.07.013","journal-title":"Int J Surg"},{"key":"5378_CR20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:698\u2013702. https:\/\/doi.org\/10.1136\/bmj.c332","journal-title":"BMJ"},{"key":"5378_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00198-013-2610-4","volume":"25","author":"K Ganda","year":"2014","unstructured":"Ganda K, Schaffer A, Pearson S, Seibel MJ (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int 25:1345\u20131355. https:\/\/doi.org\/10.1007\/s00198-013-2610-4","journal-title":"Osteoporos Int"},{"key":"5378_CR22","first-page":"e81","volume":"7","author":"V Ducoulombier","year":"2015","unstructured":"Ducoulombier V, Luraschi H, Forzy G et al (2015) Contribution of phone follow-up to improved adherence to oral osteoporosis treatment. Am J Pharm Benefits 7:e81\u2013e89 https:\/\/ajmc.s3.amazonaws.com\/_media\/_pdf\/AJPB_0506_2015_Ducoulombier(final).pdf","journal-title":"Am J Pharm Benefits"},{"key":"5378_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11657-018-0451-7","volume":"13","author":"S-Y Tamechika","year":"2018","unstructured":"Tamechika S-Y, Sasaki K, Hayami Y et al (2018) Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. Arch Osteoporos 13:67. https:\/\/doi.org\/10.1007\/s11657-018-0451-7","journal-title":"Arch Osteoporos"},{"key":"5378_CR24","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s00198-016-3681-9","volume":"27","author":"P Cram","year":"2016","unstructured":"Cram P, Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Roblin DW, Wright NC, Jones MP, Saag KG, PAADRN Investigators (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513\u20133524. https:\/\/doi.org\/10.1007\/s00198-016-3681-9","journal-title":"Osteoporos Int"},{"key":"5378_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/jbmr.3425","volume":"33","author":"MI Danila","year":"2018","unstructured":"Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, Allison JJ, Anderson FA, Wyman A, Greenspan SL, LaCroix A, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Curtis JR, Warriner AH, Wright NC, Saag KG (2018) Evaluation of a multimodal, direct-to-patient educational intervention targeting barriers to osteoporosis care: a randomized clinical trial. J Bone Miner Res 33:763\u2013772. https:\/\/doi.org\/10.1002\/jbmr.3425","journal-title":"J Bone Miner Res"},{"key":"5378_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00198-017-4340-5","volume":"29","author":"P van den Berg","year":"2018","unstructured":"van den Berg P, van Haard PMM, van der Veer E et al (2018) A dedicated fracture liaison service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates. Osteoporos Int 29:813\u2013824. https:\/\/doi.org\/10.1007\/s00198-017-4340-5","journal-title":"Osteoporos Int"},{"key":"5378_CR27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00198-015-3038-9","volume":"26","author":"ML Bianchi","year":"2015","unstructured":"Bianchi ML, Duca P, Vai S, Guglielmi G, Viti R, Battista C, Scillitani A, Muscarella S, Luisetto G, Camozzi V, Nuti R, Caffarelli C, Gonnelli S, Albanese C, de Tullio V, Isaia G, D'Amelio P, Broggi F, Croci M (2015) Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int 26:1629\u20131638. https:\/\/doi.org\/10.1007\/s00198-015-3038-9","journal-title":"Osteoporos Int"},{"key":"5378_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128063","volume":"10","author":"A LeBlanc","year":"2015","unstructured":"LeBlanc A, Wang AT, Wyatt K, Branda ME, Shah ND, van Houten H, Pencille L, Wermers R, Montori VM (2015) Encounter decision aid vs. clinical decision support or usual care to support patient-centered treatment decisions in osteoporosis: the osteoporosis choice randomized trial II. PLoS One 10:e0128063. https:\/\/doi.org\/10.1371\/journal.pone.0128063","journal-title":"PLoS One"},{"key":"5378_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3899\/jrheum.120908","volume":"40","author":"S Roux","year":"2013","unstructured":"Roux S, Beaulieu M, Beaulieu MC, Cabana F, Boire G (2013) Priming primary care physicians to treat osteoporosis after a fragility fracture: an integrated multidisciplinary approach. J Rheumatol 40:703\u2013711. https:\/\/doi.org\/10.3899\/jrheum.120908","journal-title":"J Rheumatol"},{"key":"5378_CR30","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.7150\/ijms.5359","volume":"10","author":"\u015e T\u00fcz\u00fcn","year":"2013","unstructured":"T\u00fcz\u00fcn \u015e, Aky\u00fcz G, Eskiyurt N, Memi\u015f A, Kuran B, \u0130\u00e7a\u011fas\u0131o\u011flu A, Sarpel T, \u00d6zdemir F, \u00d6zgirgin N, G\u00fcnayd\u0131n R, Cak\u00e7\u0131 A, Yurtkuran M (2013) Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study. Int J Med Sci 10:1880\u20131887. https:\/\/doi.org\/10.7150\/ijms.5359","journal-title":"Int J Med Sci"},{"key":"5378_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40520-016-0538-1","volume":"28","author":"S Gonnelli","year":"2016","unstructured":"Gonnelli S, Caffarelli C, Rossi S, di Munno O, Malavolta N, Isaia G, Muratore M, D'Avola G, Gatto S, Minisola G, Nuti R (2016) How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study. Aging Clin Exp Res 28:459\u2013468. https:\/\/doi.org\/10.1007\/s40520-016-0538-1","journal-title":"Aging Clin Exp Res"},{"key":"5378_CR32","first-page":"67","volume":"49","author":"A Oral","year":"2015","unstructured":"Oral A, Lorenc R (2015) Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: a multicenter, prospective, parallel group study. Acta Orthop Traumatol Turc 49:67\u201374","journal-title":"Acta Orthop Traumatol Turc"},{"key":"5378_CR33","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-014-2659-8","volume":"25","author":"AGG Stuurman-Bieze","year":"2014","unstructured":"Stuurman-Bieze AGG, Hiddink EG, Van Boven JFM (2014) Proactive pharmaceutical care interventions decrease patients\u2019 nonadherence to osteoporosis medication. Osteoporos Int 25:1807\u20131812. https:\/\/doi.org\/10.1007\/s00198-014-2659-8","journal-title":"Osteoporos Int"},{"key":"5378_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-016-0262-7","volume":"11","author":"P Seuffert","year":"2016","unstructured":"Seuffert P, Sagebien CA, McDonnell M (2016) Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice. Arch Osteoporos 11:1\u20136. https:\/\/doi.org\/10.1007\/s11657-016-0262-7","journal-title":"Arch Osteoporos"},{"key":"5378_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009012","volume":"96","author":"DE Beaton","year":"2017","unstructured":"Beaton DE, Mamdani M, Zheng H, Jaglal S, Cadarette SM, Bogoch ER, Sale JEM, Sujic R, Jain R, Ontario Osteoporosis Strategy Fracture Clinic Screening Program Evaluation Team (2017) Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program: an interrupted time series analysis. Medicine (Baltimore) 96:e9012. https:\/\/doi.org\/10.1097\/MD.0000000000009012","journal-title":"Medicine (Baltimore)"},{"key":"5378_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354. https:\/\/doi.org\/10.1016\/j.bone.2013.10.006","journal-title":"Bone"},{"key":"5378_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cct.2012.10.002","volume":"34","author":"SW Edmonds","year":"2013","unstructured":"Edmonds SW, Wolinsky FD, Christensen AJ et al (2013) The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health. Contemp Clin Trials 34:90\u2013100. https:\/\/doi.org\/10.1016\/j.cct.2012.10.002","journal-title":"Contemp Clin Trials"},{"key":"5378_CR38","unstructured":"Schulz KF, Altman DG, Moher D, et al. (2013) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials of TO. Ann Intern Med 1996"},{"key":"5378_CR39","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00198-013-2573-5","volume":"25","author":"AL Jensen","year":"2014","unstructured":"Jensen AL, Lomborg K, Wind G et al (2014) Effectiveness and characteristics of multifaceted osteoporosis group education-a systematic review. Osteoporos Int 25:1209\u20131224. https:\/\/doi.org\/10.1007\/s00198-013-2573-5","journal-title":"Osteoporos Int"},{"key":"5378_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archinternmed.2011.1977","volume":"172","author":"DH Solomon","year":"2012","unstructured":"Solomon DH, Iversen MD, Avorn J et al (2012) Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 172:477\u2013483. https:\/\/doi.org\/10.1001\/archinternmed.2011.1977","journal-title":"Arch Intern Med"},{"key":"5378_CR41","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00198-017-3946-y","volume":"28","author":"J-C Morfeld","year":"2017","unstructured":"Morfeld J-C, Vennedey V, M\u00fcller D, Pieper D, Stock S (2017) Patient education in osteoporosis prevention: a systematic review focusing on methodological quality of randomised controlled trials. Osteoporos Int 28:1779\u20131803. https:\/\/doi.org\/10.1007\/s00198-017-3946-y","journal-title":"Osteoporos Int"},{"key":"5378_CR42","doi-asserted-by":"publisher","unstructured":"Presley B, Groot W, Pavlova M (2018) Pharmacy-led interventions to improve medication adherence among adults with diabetes: a systematic review and meta-analysis. Res Soc Adm Pharm:1\u201311. https:\/\/doi.org\/10.1016\/j.sapharm.2018.09.021","DOI":"10.1016\/j.sapharm.2018.09.021"},{"key":"5378_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11916-015-0498-8","volume":"19","author":"EK Seng","year":"2015","unstructured":"Seng EK, Rains JA, Nicholson RA, Lipton RB (2015) Improving medication adherence in migraine treatment. Curr Pain Headache Rep 19:1\u20137. https:\/\/doi.org\/10.1007\/s11916-015-0498-8","journal-title":"Curr Pain Headache Rep"},{"key":"5378_CR44","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/1060028018770622","volume":"52","author":"BL Bowers","year":"2018","unstructured":"Bowers BL, Drew AM, Verry C (2018) Impact of pharmacist-physician collaboration on osteoporosis treatment rates. Ann Pharmacother 52:876\u2013883. https:\/\/doi.org\/10.1177\/1060028018770622","journal-title":"Ann Pharmacother"},{"key":"5378_CR45","unstructured":"Jameson JP, Baty PJ (2010) Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care"},{"key":"5378_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/NOR.0000000000000399","volume":"36","author":"S Chow","year":"2017","unstructured":"Chow S (2017) Nurse practitioner fracture liaison role: a concept analysis. Orthop Nurs 36:385\u2013391. https:\/\/doi.org\/10.1097\/NOR.0000000000000399","journal-title":"Orthop Nurs"},{"key":"5378_CR47","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.sapharm.2016.10.004","volume":"13","author":"LS Toh","year":"2017","unstructured":"Toh LS, Lai PSM, Othman S, Wong KT, Low BY, Anderson C (2017) An analysis of inter-professional collaboration in osteoporosis screening at a primary care level using the D\u2019Amour model. Res Soc Adm Pharm 13:1142\u20131150. https:\/\/doi.org\/10.1016\/j.sapharm.2016.10.004","journal-title":"Res Soc Adm Pharm"},{"key":"5378_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40266-014-0194-0","volume":"31","author":"ECK Tan","year":"2014","unstructured":"Tan ECK, George J, Stewart K, Elliott RA (2014) Improving osteoporosis management in general practice: a pharmacist-led drug use evaluation program. Drugs Aging 31:703\u2013709. https:\/\/doi.org\/10.1007\/s40266-014-0194-0","journal-title":"Drugs Aging"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05378-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05378-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:27:20Z","timestamp":1620044840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05378-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5378"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05378-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"8 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jean-Yves Reginster has received research grants from IBSA-Gen\u00e9vrier, Mylan, CNIEL, and Radius Health through institution, has received advisory board or consulting fees from IBSA-Gen\u00e9vrier, Mylan, Radius Health, and Pierre Fabre, and has received lecture fees from IBSA-Gen\u00e9vrier, Mylan, CNIEL, and Dairy Research Council (DRC). Micka\u00ebl Hiligsmann has received research grants from Amgen, Bayer, Radius Health, and Theramex through institution. The other authors have no conflict of interest relevant to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}